Roméo et Juliette de William Shakespeare à la Comédie-Française (2015-2016) : Quand une tragédie mythique devient une tragi-comédie

in Shakespeare en devenir (2019), 14(2019),

How does the production of Romeo and Juliet designed and directed by Éric Ruf, the administrator of the Comédie-Française since 2014, figure out William Shakespeare’s tragedy in an unexpected way? And how ... [more ▼]

How does the production of Romeo and Juliet designed and directed by Éric Ruf, the administrator of the Comédie-Française since 2014, figure out William Shakespeare’s tragedy in an unexpected way? And how does it transform the tragedy into a tragi-comedy? These are questions that the following article tries to answer. The first and major part of the study focuses on Éric Ruf’s parti pris concerning the myth that Romeo and Juliet has become over time. What is the stage-director’s position vis-à-vis the Shakespearean text and what is the interpretation he shares with his audience? What is the gap between the original script – here in François-Victor Hugo’s translation – and the audio-visual adaptations of the play? Furthermore, how does Juliette (Suliane Brahim) seem to be the heroine of a family vendetta while Roméo (Jérémy Lopez) has more of the anti-hero? Finally how does Éric Ruf compose the mythic balcony scene and thwart the stereotypes about it? The last part of the article deals with the music partition that is omnipresent in the performance. How does it account for Éric Ruf’s dramaturgical vision and contribute to overturn the myth? [less ▲]

Der Romzug Kaiser Heinrichs VII. (29. September 1310 - 24. August 1313)

in Margue, Michel; Pauly, Michel; Schmid, Wolfgang (Eds.) Der Weg zur Kaiserkrone. Der Romzug Heinrichs VII. in der Darstellung Erzbischof Balduins von Trier (2009)

ROS homeostasis in a dynamic model: How to save PD neuron?

Poster (2014, December)

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

in Molecular Cancer (2017), 8(june),

Background: Most melanoma patients with BRAFV600E positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of ... [more ▼]

Background: Most melanoma patients with BRAFV600E positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the treatment. For patients insufficiently responding to BRAF and MEK inhibitors, there is an ongoing need for new treatment targets. Cellular metabolism is such a promising new target line: mutant BRAFV600E has been shown to affect the metabolism. Methods: Time course experiments and a series of western blots were performed in a panel of BRAFV600E and BRAFWT/ NRASmut human melanoma cells, which were incubated with BRAF and MEK1 kinase inhibitors. siRNA approaches were used to investigate the metabolic players involved. Reactive oxygen species (ROS) were measured by confocal microscopy and AZD7545, an inhibitor targeting PDKs (pyruvate dehydrogenase kinase) was tested. Results: We show that inhibition of the RAS/RAF/MEK/ERK pathway induces phosphorylation of the pyruvate dehydrogenase PDH-E1α subunit in BRAFV600E and in BRAFWT/NRASmut harboring cells. Inhibition of BRAF, MEK1 and siRNA knock-down of ERK1/2 mediated phosphorylation of PDH. siRNA-mediated knock-down of all PDKs or the use of DCA (a pan-PDK inhibitor) abolished PDH-E1α phosphorylation. BRAF inhibitor treatment also induced the upregulation of ROS, concomitantly with the induction of PDH phosphorylation. Suppression of ROS by MitoQ suppressed PDH-E1α phosphorylation, strongly suggesting that ROS mediate the activation of PDKs. Interestingly, the inhibition of PDK1 with AZD7545 specifically suppressed growth of BRAF-mutant and BRAF inhibitor resistant melanoma cells. Conclusions: In BRAFV600E and BRAFWT/NRASmut melanoma cells, the increased production of ROS upon inhibition of the RAS/RAF/MEK/ERK pathway, is responsible for activating PDKs, which in turn phosphorylate and inactivate PDH. As part of a possible salvage pathway, the tricarboxylic acid cycle is inhibited leading to reduced oxidative metabolism and reduced ROS levels. We show that inhibition of PDKs by AZD7545 leads to growth suppression of BRAF-mutated and -inhibitor resistant melanoma cells. Thus small molecule PDK inhibitors such as AZD7545, might be promising drugs for combination treatment in melanoma patients with activating RAS/RAF/MEK/ERK pathway mutations (50% BRAF, 25% NRASmut, 11.9% NF1mut). [less ▲]

ROS-Defender: SDN-based Security Policy Enforcement for Robotic Applications

in IEEE Workshop on the Internet of Safe Things, Co-located with IEEE Security and Privacy 2019 (2019, May)

Abstract—In this paper we propose ROS-Defender, a holistic approach to secure robotics systems, which integrates a Security Event Management System (SIEM), an intrusion prevention system (IPS) and a ... [more ▼]

Abstract—In this paper we propose ROS-Defender, a holistic approach to secure robotics systems, which integrates a Security Event Management System (SIEM), an intrusion prevention system (IPS) and a firewall for a robotic system. ROS-Defender combines anomaly detection systems at application (ROS) level and network level, with dynamic policy enforcement points using software defined networking (SDN) to provide protection against a large class of attacks. Although SIEMs, IPS, and firewall have been previously used to secure computer networks, ROSDefender is applying them for the specific use case of robotic systems, where security is in many cases an afterthought. [less ▲]

ROS-management in Parkinson’s disease: Dynamic blue-print domino-based model and design principles study. Dynamic modelling of ROS management and ROS-induced mitophagy

Poster (2014, October)

Rosa Zeiten? Eine diskursanalytische Untersuchung zur Homosexualität in der BRD unter besonderer Berücksichtigung der 1970er und 1980er Jahre

Doctoral thesis (2010)

Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway

in British Journal of Pharmacology (2006), 148(4), 544-52

Nitrate tolerance is associated with an enhanced superoxide anion (O(2)(-)) production and may be attenuated by statins as they interact with the two main endothelial NO synthase (eNOS) and NAD(P)H ... [more ▼]

Nitrate tolerance is associated with an enhanced superoxide anion (O(2)(-)) production and may be attenuated by statins as they interact with the two main endothelial NO synthase (eNOS) and NAD(P)H oxidase pathways involved in this oxidative stress. Groups of wild-type (wt, C57Bl/6J) and eNOS knock-out mice (eNOS(-/-)) received rosuvastatin (20 mg kg(-1) day(-1) p.o.) for 5 weeks and a cotreatment with the statin plus nitroglycerin (NTG; 30 mg kg(-1) day(-1), subcutaneous injections b.i.d.) for the last 4 days. Another group received only NTG (30 mg kg(-1) d(-1), b.i.d. for 4 days) and finally control mice from both strains received no treatment. Rings of thoracic aortas from these groups were studied in organ baths. Relaxations to NTG (0.1 nM-0.1 mM) were determined on thromboxane analogue (U44619)-precontracted rings and O(2)(-) production (RLU 5 s(-1) mg(-1) of total protein content) was assessed in aorta homogenates with the lucigenin-enhanced chemiluminescence technique. Reverse transcriptase-polymerase chain reaction analysis was performed on aortas from both mice strains. In vivo NTG treatment induced a significant rightward shift of the concentration-effect curve to NTG compared to control group. There was, however, no cross-tolerance with non-nitrate sources of NO (unaltered response to acetylcholine in wt group). The rosuvastatin + NTG cotreatment was able to protect against the development of nitrate tolerance in both mice strains and L-mevalonate abolished this protective effect of rosuvastatin. In vivo treatment with apocynin, a purported NAD(P)H oxidase inhibitor, also produced a similar protection to that observed with rosuvastatin in both strains.Superoxide anion formation was increased after NTG treatment in both mice strains and the rosuvastatin + NTG cotreatment was able to reduce that production. Moreover, rosuvastatin treatment abolished the increase in gp91phox mRNA (an endothelial membrane NAD(P)H oxidase subunit) expression induced by in vivo exposure to NTG. These findings suggest that long-term rosuvastatin treatment protects against nitrate tolerance by counteracting NTG-induced increase in O(2)(-) production, probably via a direct interaction with the NAD(P)H oxidase pathway. [less ▲]

Rotameter: A Non-Invasive and Simple Device for an In Vivo Analysis of Rotational Knee Laxity

in 44th Gesellschaft für Biomedizinische Technik (DGBMT) (2010)

Rotation capacity of composite joints for slim-floor beams

in Stahlbau (2019), 88(7), 675--684

The analysis of a composite beam-to-column structure requires knowledge about, on the one hand, the behaviour of beams and columns and, on the other, the joints between such elements. For beam-to-column ... [more ▼]

The analysis of a composite beam-to-column structure requires knowledge about, on the one hand, the behaviour of beams and columns and, on the other, the joints between such elements. For beam-to-column joints, for example, the lack of appropriate design rules forces structural engineers to model joints as pinned, despite the fact that a certain joint rigidity and bending resistance is available because of the upper reinforced concrete slab. In this context, a research program with experimental and numerical investigations was initiated at the University of Luxembourg [1]. This aim of this research was to identify the influence of two major joint components – the reinforced concrete slab and the steelwork connection – on the behaviour of composite joints under a hogging bending moment. Eight experimental tests were performed on... [less ▲]